Trials / Withdrawn
WithdrawnNCT02790710
Brief Intervention for OCD Fears
- Status
- Withdrawn
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- New York State Psychiatric Institute · Academic / Other
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
The study will test the efficacy of propranolol or placebo, administered after reactivation of a previously acquired obsessive-compulsive disorder (OCD) fear, in reducing fear and avoidance in OCD.
Detailed description
Twenty subjects with OCD will be enrolled in the study. Participants will complete baseline assessments of fear and avoidance. Participants will be randomly assigned to a single dose of propranolol 40mg or placebo, administered immediately after a fear reactivation procedure. Primary outcome assessment will be OCD symptoms and avoidance behavior in a behavioral avoidance task 2 weeks after the intervention
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Propanolol | Active treatment |
| DRUG | Placebo |
Timeline
- Start date
- 2016-06-01
- Primary completion
- 2023-04-01
- Completion
- 2023-04-01
- First posted
- 2016-06-06
- Last updated
- 2023-04-18
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02790710. Inclusion in this directory is not an endorsement.